Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives.

Ibuprofen is crystallized from a .delta.H.gtoreq.8 liquid such as a C.sub.1 to C.sub.3 -alkanol, e.g., methanol, containing solutions thereof to obtain ibuprofen crystals which are equant (cube, sphere or grain) in shape, which ibuprofen crystals have larger average partile size, higher bulk density, lower bulk volume and improved flow properties compared to previously known bulk ibuprofen crystalline materials.

Fumaric acid is added in amounts sufficient to reduce the burn sensation commonly associated with propionic acid derivatives.

A novel neomorphic form of ibuprofen and processes for preparing the ibuprofen are provided. The neomorphic form is characterized by having a distinctively less bitter taste and causes less burning sensation upon swallowing. The neomorphic form of ibuprofen is an amorphous ibuprofen and is prepared by imparting kinetic energy to supercooled ibuprofen.

Ibuprofen tablets/caplets formed by wet granulation of the ibuprofen characterized by a dissolution profile maintained stable on aging by incorporating croscarmellose sodium separately into the wet granulation and the compression mix and further incorporating sodium lauryl sulfate into the compression mix.

(S)-ibuprofen may be separated from a mixture of (S)-ibuprofen and (R)-ibuprofen in high yield and enantiomeric purity in a single resolution step using an N-alkyl-D-glucamine as the resolving agent.

A process for obtaining a substantially pure enantiomer of ibuprofen is described. The process utilizes first an enantiomerically enriched mixture of ibuprofen obtained from kinetic resolution, diastereomeric crystallization or asymmetric synthesis processes. This enriched mixture is dissolved in a solvent and solid racemic ibuprofen is separated, leaving a mother liquid comprising the solvent and the enriched enantiomer substantially free of the other enantiomer.

The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.

Ibuprofen-aspirin compounds useful in treating aspirin or ibuprofen-treatable conditions and hydroxymethylacylfulvene analogs useful as antitumor drugs.

Palatable ibuprofen aqueous base solutions are described which contain dissolved therein ibuprofen and hydroxypropyl beta cyclodextrin, which form an inclusion complex, and sweeteners to mask the sour taste common to organic acids.